Limits...
Combined Therapy against Recurrent Hemangiopericytoma: A Case Report.

Li XD, Jiang JT, Wu CP - Cancer Biol Med (2012)

Bottom Line: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China A patient with a seven-year history of recurrent metastatic hemangiopericytoma (HPC) was admitted.During his treatment, he received surgical resection, radiotherapy, radiofrequency hyperthermia and chemotherapy using combined doxorubicin, dacarbazin, vincristine, ginsenoside Rg3, and recombinant human endostatin.This synergistic method provides an encouraging model for treating HPC.

View Article: PubMed Central - PubMed

ABSTRACT
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China A patient with a seven-year history of recurrent metastatic hemangiopericytoma (HPC) was admitted. During his treatment, he received surgical resection, radiotherapy, radiofrequency hyperthermia and chemotherapy using combined doxorubicin, dacarbazin, vincristine, ginsenoside Rg3, and recombinant human endostatin. This synergistic method provides an encouraging model for treating HPC.

No MeSH data available.


Related in: MedlinePlus

The disease was diagnosed as well-differentiated HPC. HPC are characterized histologically by spindle-shaped tumor cells (slender arrow) separated by numerous capillaries (bold arrow).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3643657&req=5

f1: The disease was diagnosed as well-differentiated HPC. HPC are characterized histologically by spindle-shaped tumor cells (slender arrow) separated by numerous capillaries (bold arrow).

Mentions: The patient was a 42-year-old man with a 7-year history of recurrent metastatic HPC. A CT scan during a physical examination in 2002 revealed a mass in the patient’s liver. He received a complete surgical resection of the mass that was pathologically and immunohistochemically confirmed as HPC (Figure 1). No lymph node or distant metastasis was found, and the disease was labeled as stage I (G0TxN0M0).


Combined Therapy against Recurrent Hemangiopericytoma: A Case Report.

Li XD, Jiang JT, Wu CP - Cancer Biol Med (2012)

The disease was diagnosed as well-differentiated HPC. HPC are characterized histologically by spindle-shaped tumor cells (slender arrow) separated by numerous capillaries (bold arrow).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3643657&req=5

f1: The disease was diagnosed as well-differentiated HPC. HPC are characterized histologically by spindle-shaped tumor cells (slender arrow) separated by numerous capillaries (bold arrow).
Mentions: The patient was a 42-year-old man with a 7-year history of recurrent metastatic HPC. A CT scan during a physical examination in 2002 revealed a mass in the patient’s liver. He received a complete surgical resection of the mass that was pathologically and immunohistochemically confirmed as HPC (Figure 1). No lymph node or distant metastasis was found, and the disease was labeled as stage I (G0TxN0M0).

Bottom Line: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China A patient with a seven-year history of recurrent metastatic hemangiopericytoma (HPC) was admitted.During his treatment, he received surgical resection, radiotherapy, radiofrequency hyperthermia and chemotherapy using combined doxorubicin, dacarbazin, vincristine, ginsenoside Rg3, and recombinant human endostatin.This synergistic method provides an encouraging model for treating HPC.

View Article: PubMed Central - PubMed

ABSTRACT
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China A patient with a seven-year history of recurrent metastatic hemangiopericytoma (HPC) was admitted. During his treatment, he received surgical resection, radiotherapy, radiofrequency hyperthermia and chemotherapy using combined doxorubicin, dacarbazin, vincristine, ginsenoside Rg3, and recombinant human endostatin. This synergistic method provides an encouraging model for treating HPC.

No MeSH data available.


Related in: MedlinePlus